



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/609,383

07/01/2003

Richard J. Feldmann

3279-Z

4498

23364 7590 05/28/2008

BACON & THOMAS, PLLC
625 SLATERS LANE
FOURTH FLOOR
ALEXANDRIA, VA 22314

EXAMINER

BRUSCA, JOHN S

ART UNIT

PAPER NUMBER

1631

MAIL DATE

DELIVERY MODE

05/28/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/609,383	Applicant(s) FELDMANN, RICHARD J.	
	Examiner John S. Brusca	Art Unit 1631	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 27 March 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-12 is/are pending in the application.
- 4a) Of the above claim(s) 3-12 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, and 2 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>10/04/2007</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1631

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 27 March 2009 has been entered.

Status of the Claims

2. Claims 1-12 are pending.

Claims 3-12 are withdrawn

Claims 1 and 2 are rejected.

Specification

3. The objection to the specification in the Office action mailed 28 September 2007 is withdrawn in view of the sequence listing and CRF filed 27 March 2008. The sequence listing and CRF have been entered into the application file.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1631

5. For the purpose of examination the claims have been interpreted as requiring only computer-mediated sequence data analysis, without a requirement of physical manipulation of polynucleotides.

6. Claims 1 and 2 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention.

In *In re Wands* (8 USPQ2d 1400 (CAFC 1988)) the CAFC considered the issue of enablement in molecular biology. The CAFC summarized eight factors to be considered in a determination of "undue experimentation." These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims.

In considering the factors for the instant claims:

a) Quantity of experimentation: The only utility asserted by the specification is to use connectron symmetries to predict control of gene expression (see for example pages 11, 15, and 16 of the specification). In order to practice the claimed invention one of skill in the art must identify and use a connectron to predict regulation of gene expression. In some embodiments changes in connectron behavior that correlate with changes in gene expression is monitored or effected. For the reasons discussed below, there would be an unpredictable amount of experimentation required to practice the claimed invention.

b) The amount of direction or guidance presented: The claimed invention is a method of

Art Unit: 1631

identification of sequences that have a connectron relationship and act to modulate gene expression. On page 3, the specification defines connectrons as a tetradic structure between two sequences in an RNA transcript of a genomic sequence and two sequences in double stranded genomic DNA. The specification speculates without evidence on page 7 that triple-stranded (triplex) structures will form between RNA and double stranded DNA in chromatin where connectron symmetries of identical sequences are identified. The specification does not provide guidance that there are any limitations on formation of triplex structures, and only implies that regions of RNA with identical sequence to one strand of a double stranded DNA sequence will form triplex structures. The specification does not address why all RNA transcripts of genes which inherently have identical sequences would not form a continuous triplex structure with the gene from which it is transcribed. The specification provides guidance to identify connectron symmetries in genomic sequences. The specification does not provide detailed guidance to use identified connectron symmetries because the specification does not show whether or not connectrons form within cells or have an effect on gene expression. The specification does not provide specific guidance for monitoring or effecting changes in connectron behavior that correlate with gene expression.

c) The presence or absence of working examples: The specification provides working examples of identification of connectron symmetries by computer-mediated searching of genomic sequences. However, the specification does not provide evidence that connectron symmetries in genomic sequences result in formation of triplex RNA-DNA structures in which the RNA and DNA have identical sequences, or that if connectron triplex structures do exist that

Art Unit: 1631

connectrons control gene expression. The specification does not provide working examples of using identified connectron symmetries to predict effects on gene expression. The specification does not provide working examples of monitoring or effecting changes in connectron behavior that correlate with gene expression.

d) The nature of the invention: The nature of the invention, gene expression control, is complex.

e) The state of the prior art: One of skill in the art, after reading the specification, would not know that connectron symmetries identified by computer-mediated searches of genomic sequences would allow for prediction of gene expression of genes that have connectron symmetries. The specification does not provide experimental evidence that connectron symmetries cause modulation of gene expression. Neither the prior art nor post-filing art shows connectrons. Mattick (published in 2001, one year after the effective instant filing date) reviews effects of RNA molecules on gene regulation. Mattick does not show connectrons as defined in the instant specification. Chan et al. reviews triplex DNA formation. Chan et al. shows in figures 1A-C that short stretches of oligonucleotides may form parallel or antiparallel triplex structures. Chan et al. shows in figures 1B that parallel triplex forming oligonucleotides form bonds between C and T residues of the oligonucleotide and G and A residues of the double stranded DNA molecule. Figure 1C shows that antiparallel triplex forming oligonucleotides form bonds between A, G, and T residues of the oligonucleotide and A, G, and A residues of the double stranded DNA. Chan et al. characterize the limited range of base pairing possibilities in triplex structures as pyrimidine binding motifs or purine binding motifs. Chan et al. describe on pages

Art Unit: 1631

268-273 the unpredictability and difficulty of forming desired triplex structures that are limited to the purine motif or the pyrimidine motif. Chan et al. does not show a mechanism that allows for triplex structures to form with regions of identical sequences between an RNA transcript and a region of double stranded DNA, as required for connectron formation as defined in the instant specification.

f) The relative skill of those in the art: The skill of those in the art of gene expression is high.

g) The predictability of the art: The predictability of the relationship of connectron symmetries and gene expression is unknown in the prior art and is not described in the instant specification.

h) The breadth of the claims: The claims are broad in that they are drawn to identification and modulation of connectron symmetries whose relationship to gene expression is not established.

The skilled practitioner would first turn to the instant specification for guidance in using the claimed invention. However, the specification lacks any evidence that connectrons form in cells or that connectron symmetries are related to gene expression. As such, the skilled practitioner would turn to the prior art for such guidance, however the prior art does not discuss connectron symmetries. Chan et al. shows that triplex formation occurs only with oligonucleotides with a purine rich or pyrimidine rich motif, rather than with any identical sequence as suggested in the specification. Finally, said practitioner would turn to trial and error experimentation to determine a relationship between connectron symmetries and gene

Art Unit: 1631

expression. Such amounts to undue experimentation.

Response to Arguments

7. Applicant's arguments filed 27 March 2008 have been fully considered but they are not persuasive.

The applicants refer to the Vacatur mailed 28 September 2006 in Application No. 09/866925 in which the Board states that one of skill in the art would be enabled to generate data of connectron symmetries from a genome sequence. However, the applicants have not provided any evidence in the specification or their arguments that the triplex structure of connectrons form, or that knowledge of connectron symmetries can be used to predict or control gene expression. The applicants emphasize that the specification provides a method of identification of connectron symmetries in genomic sequences. It is agreed that the specification provides a method of identification of connectron symmetries, however the specification does not enable the use of identified connectron symmetries because the specification does not establish that connectrons form in cells or that connectron symmetries allow for prediction of gene expression or that connectrons may be manipulated to control gene expression. The applicants state that the USPTO has a burden to prove that connectrons do not form. Such is not the case, and the rejection cites prior art evidence that triplex structures hypothesized by the specification are not known to form by the prior art rules of triplex polynucleotide structure formation. As such the USPTO has shown compelling evidence the prior art cannot be relied upon to enable the instant claimed subject matter. Enablement therefore must derive from the specification at the time of filing, which the above rejection shows is lacking. The applicants have not provided evidence

Art Unit: 1631

that connectrons form or regulate gene expression. The applicants attempt to argue that the Wands factors considered in the above rejection should only be applied to subject matter considered in *In re Wands*. The MPEP has adopted the methodology of *In re Wands* as a useful set of factors to consider for satisfaction of the enablement requirement of 35 U.S.C. 112 first paragraph as noted below:

2164.01 [R-5] Test of Enablement

Any analysis of whether a particular claim is supported by the disclosure in an application requires a determination of whether that disclosure, when filed, contained sufficient information regarding the subject matter of the claims as to enable one skilled in the pertinent art to make and use the claimed invention. The standard for determining whether the specification meets the enablement requirement was cast in the Supreme Court decision of *Mineral Separation v. Hyde*, 242 U.S. 261, 270 (1916) which postured the question: is the experimentation needed to practice the invention undue or unreasonable? That standard is still the one to be applied. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

Accordingly, even though the statute does not use the term “undue experimentation,” it has been interpreted to require that the claimed invention be enabled so that any person skilled in the art can make and use the invention without undue experimentation. *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988). See also *United States v. Teletronics, Inc.*, 857 F.2d 778, 785, 8 USPQ2d 1217, 1223 (Fed. Cir. 1988) (“The test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the

patent coupled with information known in the art without undue experimentation.”). A patent need not teach, and preferably omits, what is well known in the art. *In re Buchner*, 929 F.2d 660, 661, 18 USPQ2d 1331, 1332 (Fed. Cir. 1991); *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1384, 231 USPQ 81, 94 (Fed. Cir. 1986), cert. denied, 480 U.S. 947 (1987); and *Lindemann Maschinenfabrik GMBH v. American Hoist & Derrick Co.*, 730 F.2d 1452, 1463, 221 USPQ 481, 489 (Fed. Cir. 1984). >Any part

Art Unit: 1631

of the specification can support an enabling disclosure, even a background section that discusses, or even disparages, the subject matter disclosed therein. *Callicrate v. Wadsworth Mfg., Inc.*, 427 F.3d 1361, 77 USPQ2d 1041 (Fed. Cir. 2005)(discussion of problems with a prior art feature does not mean that one of ordinary skill in the art would not know how to make and use this feature).< Determining enablement is a question of law based on underlying factual findings. *In re Vaeck*, 947 F.2d 488, 495, 20 USPQ2d 1438, 1444 (Fed. Cir. 1991); *Atlas Powder Co. v. E.I. du Pont de Nemours & Co.*, 750 F.2d 1569, 1576, 224 USPQ 409, 413 (Fed. Cir. 1984).

UNDUE EXPERIMENTATION

The fact that experimentation may be complex does not necessarily make it undue, if the art typically engages in such experimentation. *In re Certain Limited-Charge Cell Culture Microcarriers*, 221 USPQ 1165, 1174 (Int'l Trade Comm'n 1983), *aff'd. sub nom., Massachusetts Institute of Technology v. A.B. Fortia*, 774 F.2d 1104, 227 USPQ 428 (Fed. Cir. 1985). See also *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404. The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. *In re Angststadt*, 537 F.2d 498, 504, 190 USPQ 214, 219 (CCPA 1976).

2164.01(a) Undue Experimentation Factors

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to:

- (A) The breadth of the claims;
- (B) The nature of the invention;
- (C) The state of the prior art;
- (D) The level of one of ordinary skill;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;

Art Unit: 1631

(G) The existence of working examples; and

(H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

In *re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) (reversing the PTO's determination that claims directed to methods for detection of hepatitis B surface antigens did not satisfy the enablement requirement). In *Wands*, the court noted that there was no disagreement as to the facts, but merely a disagreement as to the interpretation of the data and the conclusion to be made from the facts. In *re Wands*, 858 F.2d at 736-40, 8 USPQ2d at 1403-07. The Court held that the specification was enabling with respect to the claims at issue and found that "there was considerable direction and guidance" in the specification; there was "a high level of skill in the art at the time the application was filed;" and "all of the methods needed to practice the invention were well known." 858 F.2d at 740, 8 USPQ2d at 1406. After considering all the factors related to the enablement issue, the court concluded that "it would not require undue experimentation to obtain antibodies needed to practice the claimed invention." *Id.*, 8 USPQ2d at 1407. It is improper to conclude that a disclosure is not enabling based on an analysis of only one of the above factors while ignoring one or more of the others. The examiner's analysis must consider all the evidence related to each of these factors, and any conclusion of nonenablement must be based on the evidence as a whole. 858 F.2d at 737, 740, 8 USPQ2d at 1404, 1407.

A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In *re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993).

The determination that "undue experimentation" would have been needed to make and use the claimed invention is not a single, simple factual determination. Rather, it is a conclusion reached by weighing all the above noted factual considerations. In *re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404. These factual considerations are discussed more fully in MPEP § 2164.08 (scope or breadth of the claims), § 2164.05(a)

Art Unit: 1631

(nature of the invention and state of the prior art), § 2164.05(b) (level of one of ordinary skill), § 2164.03 (level of predictability in the art and amount of direction provided by the inventor), § 2164.02 (the existence of working examples) and § 2164.06 (quantity of experimentation needed to make or use the invention based on the content of the disclosure).

On page 6 of their arguments, the applicants make the teleological argument that because connectron symmetries exist in genome, they must have a purpose, however it is the applicants burden to enable the use of the claimed subject matter at the time of filing, and it is not sufficient to speculate that an observed genomic sequence symmetry must be useful. The applicant has not responded to the factual information cited in the prior art of Chan et al. that is in conflict with the proposed structures of connectrons. The applicant has attached an appendix to the remarks. A review of the appendix shows that it discusses proposed experiments to test the existence of connectrons. The experiments have not been carried out. There is insufficient detail in the appendix to determine if the recombinant constructs employed would have the potential to form the connectron triple helix structures described in the specification. The appendix is therefore not persuasive.

Conclusion

8. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114.

Art Unit: 1631

See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie A. Moran can be reached on 571-272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/John S. Brusca/

Primary Examiner

Art Unit 1631

jsb